Oral: 400-1600 mg PO qDay
IM/IV: 200-400 mg/day
Oral: 200 mg PO TID
IV: 400 mg/day IV
Liver Disease, Alcohol Related
Oral: 1200-1600 mg PO qDay; no more than 24 months
IV: 200-2000 mg/day IV x 15-30 days
IM: 200 mg/day IM x 30 days
Oral: 800 mg PO BID
800 mg PO qDay
AIDS-related Myelopathy (Orphan)
800 mg/day IV x 14 days
Orphan indication sponsor
- Genopia USA, Inc; 90 Gold Street, 6N; New York, NY 10038
AIDS-related myelopathy, Alzheimer's disease, bursitis/tendinitis, depression, fibromyalgia, heart disease, intrahepatic cholestasis, liver disease, migraine headache, osteoarthritis
Several studies showed comparable effectiveness to TCAs
Standardization of product not as good in US as in Europe
Oral form has poor bioavailability; pos. studies used parenteral SAMe
Mult clinical trials showed comparable effectiveness to NSAIDS, with fewer side effects
Studies showed possibly effective for the treatment of AIDS-related myelopathy, fibromyalgia,& intrahepatic cholestasis
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
MAO inhibitor use within 14 day
Pregnancy & Lactation
Pregnancy Category: N/A
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Methyl donor in many metabolic reactions